Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders. - Ma Y; Poon E; Jin C; Martins da Costa B; Xu Y; Quazi S; Zourdoumis N; Wickremesinghe C; Chesler L; Keun HC; Nijhuis A (Cell reports, 2026)